Diseño y características basales del estudio REGUEIFA (Registro Gallego Intercéntrico de Fibrilación Auricular)

Seara, Javier García; Melchor, Laila González; Caamaño, María Vázquez; Windcheid, Emilio Fernández-Obanza; Portela, Miriam Piñeiro; Babarro, Eva González; Grandío, Pilar Cabanas; Bobin, O Duran; Delgado, Óscar Prada; Teja, Juliana Elices; Freire, Evaristo; Feijoo, Mario Gutiérrez; Castro, Olalla; Muñiz, Javier; González‐Juanatey, Carlos

doi:10.1016/j.rccl.2020.10.015

Cited by 3 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study design and methods have been previously described [8]. A total of 1007 patients were recruited between 2 January 2018 and 27 February 2020, belonging to the cohort of the REGUEIFA trial [8].…”

Section: Methodsmentioning

confidence: 99%

“…The REgistro GallEgo Intercéntrico de Fibrilación Auricular (REGUEIFA) trial is a prospective, multicenter observational registry of consecutive patients diagnosed with AF [8]. The present study was carried out to analyze and compare the clinical characteristics of patients with AF and the therapeutic strategies used according to gender in the cohort of the REGUEIFA trial.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Differences in the Clinical Profile and Management of Atrial Fibrillation According to Gender. Results of the REgistro GallEgo Intercéntrico de Fibrilación Auricular (REGUEIFA) Trial

Durán-Bobin

Elices-Teja

González‐Melchor

et al. 2021

JCM

Self Cite

View full text Add to dashboard Cite

To analyze the clinical profile and therapeutic strategy in atrial fibrillation (AF) according to gender in a contemporaneous patient cohort a prospective, multicenter observational study was performed on consecutive patients diagnosed with AF and assessed by cardiology units in the region of Galicia (Spain). A total of 1007 patients were included, of which 32.3% were women. The mean age of the women was significantly greater than that of the men (71.6 versus 65.7 years; p < 0.001), with a higher prevalence of hypertension (HTN) and valve disease. Women more often reported symptoms related to arrhythmia (28.2% in EHRA class I versus 36.4% in men), with a poorer level of symptoms (EHRA classes IIb and III). Thromboembolic risk was significantly higher among women (CHA2DS2-VASc 3 ± 1.3 versus 2 ± 1.5), in the same way as bleeding risk (HAS-BLED 0.83 ± 0.78 versus 0.64 ± 0.78) (p < 0.001), and women more often received anticoagulation therapy (94.1% versus 87.6%; p = 0.001). Rhythm control strategies proved significantly less frequent in women (55.8% versus 66.6%; p = 0.001), with a lesser electrical cardioversion (ECV) rate (18.4% versus 27.3%; p = 0.002). Perceived health status was poorer in women. Women were older and presented greater comorbidity than men, with a greater thromboembolic and bleeding risk. Likewise, rhythm control strategies were less frequent than in men, despite the fact that women had poorer perceived quality of life and were more symptomatic.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%